Durham company Aerie Pharmaceuticals Inc. (AERI:NMQ) working in Pharmaceuticals and Biotechnology sees value rise 54.7% in week ending July 23

0Comments

Value in Pharmaceuticals and Biotechnology stocks fell 0.7 percent in the week ending July 23 from the previous week.

The strongest performing Pharmaceuticals and Biotechnology company in North Carolina was Liquidia Corp. (LQDA:NAQ), sitting 1,731.5 percent higher to sell at $5.2.

Tenax Therapeutics Inc. (TENX:NAQ) fared the worst among North Carolina companies, suffering a 59.6 percent drop to $0.2646.

Among Durham companies, Novan Inc. (NOVN:NAQ) saw the highest rise in value of 292 percent in the week ending July 23.

The Medical Equipment and Services industry was the week’s best-performing industry on the market. The market is divided into 44 different industries.

Pharmaceuticals and Biotechnology was the worst-performing industry.

Healthcare and technology stocks are viewed as the safest bets for long-term gains.

Besty Kuekcer with Benzinga.com said healthcare-related stocks, such as hospital conglomerates and insurance companies, have weathered numerous economic crises and still make a profit, suggesting that they are generally a stable investment.

While technology stocks can be more risky, given the boom-bust nature of new tech companies, Kuecker recommended a diverse portfolio of tech companies to strike it big when companies succeed or sell to other larger companies.

For short-term investments, Kuecker recommended “consumer discretionary” stocks, which are sensitive to economic changes but can rise greatly on the back of a strong economy.

Nothing in this article is to be assumed as financial advice.

Individual companies can have several different types of shares across many stock markets. It is possible for different types of shares to see different results on the market.

Rank of stock market industries in week ending July 23

Industry Percentage Change Highest Positive Change Largest Negative Change
Medical Equipment and Services 11.7% 2,960.3% -97.5%
Life Insurance 7% 48.6% -91.5%
Household Goods and Home Construction 6.8% 249.9% -73.4%
Technology Hardware and Equipment 6.8% 1,615.7% -61.9%
General Industrials 6.5% 3,073.5% -80.4%
Industrial Metals and Mining 6.3% 494.7% -99.9%
Chemicals 6.2% 895.4% -70.3%
Personal Goods 6.1% 2,713% -84.4%
Industrial Engineering 6.1% 1,876% -92.3%
Real Estate Investment and Services 6% 525.9% -93.2%
Industrial Transportation 5.9% 299.1% -90.7%
Leisure Goods 5.5% 704.7% -73.2%
Tobacco 5.2% 4,071.5% -60.5%
Construction and Materials 4.7% 390.3% -99.2%
Consumer Services 4.6% 353.2% -93.9%
Oil, Gas and Coal 4.6% 999% -85.1%
Industrial Materials 4.5% 153.4% -50%
Alternative Energy 4.4% 403% -66.4%
Finance and Credit Services 4.3% 817.5% -87.6%
Telecommunications Equipment 3.9% 453.3% -96.8%
Industrial Support Services 3.9% 1,461.8% -97.8%
Investment Banking and Brokerage Services 3.8% 829% -88.7%
Mortgage Real Estate Investment Trusts 3.8% 78.4% -81.5%
Software and Computer Services 3.7% 9,075.2% -95.3%
Electronic and Electrical Equipment 3.6% 1,040.7% -99.4%
Telecommunications Service Providers 3.1% 713.6% -94.5%
Banks 2.8% 8,302.3% -93.4%
Travel and Leisure 2.8% 4,492.7% -99.1%
Real Estate Investment Trusts 2.7% 361.6% -77%
Waste and Disposal Services 2.3% 731.6% -75.1%
Beverages 2.2% 624.8% -70.9%
Health Care Providers 1.9% 14,241.2% -92.1%
Personal Care, Drug and Grocery Stores 1.9% 111% -95.8%
Food Producers 1.9% 1,168.7% -77.3%
Media 1.2% 11,338.5% -94.4%
Closed End Investments 1.2% 1,065.7% -94.5%
Aerospace and Defense 1.1% 13,894.9% -66.5%
Automobiles and Parts 1.1% 305.5% -99.7%
Precious Metals and Mining 0.9% 123.7% -81.6%
Retailers 0.2% 90,591.7% -88.1%
Open End and Miscellaneous Investment Vehicles 0.1% 227,305.5% -100%
Non-life Insurance -0.4% 1,905.1% -90.7%
Electricity -0.5% 911% -68.1%
Pharmaceuticals and Biotechnology -0.7% 4,075.3% -99.6%


Related

Craig T. Albanese, CEO

Duke Health trial finds immunotherapy delays chemotherapy in advanced colorectal cancer

A new clinical trial from Duke Health shows that first-line immunotherapy may delay or replace chemotherapy in advanced colorectal cancer cases. The findings offer hope for improved quality of life among younger patients facing aggressive forms of the disease.

Hannah Lohman, RTI Research Environmental Engineer

EPA and HHS announce actions to address microplastics in drinking water

The EPA and HHS have announced new efforts targeting microplastics in U.S. drinking water systems. RTI International staff attended as federal officials detailed regulatory plans prioritizing research funding into detection methods, impacts on health, prevention strategies, and laboratory standards.

Tim J. Gabel, President and Chief Executive Officer

RTI International examines trends and shifts in ultra-processed food consumption

RTI International highlights rising consumer awareness about ultra-processed foods (UPFs) alongside industry reformulations and emerging state-level policies restricting certain additives. The organization points out challenges surrounding inconsistent definitions while noting increased calls for transparency from both regulators and public health advocates.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from Durham Reporter.